Labcorp's Diagnostic Tool Approved by FDA for Advanced Melanoma Treatment Selection

The FDA has approved Labcorp's PGDx elio® tissue complete CDx, a companion diagnostic for advanced melanoma. This tool identifies patients with specific BRAF variants, making them eligible for targeted BRAF and BRAF/MEK inhibitor therapies. This approval is significant as it aims to improve access to personalized treatment options for advanced melanoma, a severe form of skin cancer.